STOCK TITAN

Applied Therapeutics, Inc. - $APLT STOCK NEWS

Welcome to our dedicated page for Applied Therapeutics news (Ticker: $APLT), a resource for investors and traders seeking the latest updates and insights on Applied Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Applied Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Applied Therapeutics's position in the market.

Rhea-AI Summary
Applied Therapeutics, Inc. will present at the UBS Biopharma Conference 2023 on November 9, 2023, at 2:00 p.m. ET in Miami, Florida. The presentation will be available via live webcast on the company's website, and a replay will be archived for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
conferences
-
Rhea-AI Summary
Applied Therapeutics, Inc. will host a Diabetic Cardiomyopathy expert forum on November 7, 2023. The forum will discuss the disease overview, ARISE-HF trial, and cardiac functional capacity. Key opinion leaders will be present, and the event will be webcast live.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
conferences
-
Rhea-AI Summary
Applied Therapeutics to present at the 59th EASD Annual Meeting on the potential benefit of AT-001 in treating Diabetic Cardiomyopathy (DbCM).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.37%
Tags
conferences clinical trial
Rhea-AI Summary
Applied Therapeutics, Inc. plans to submit an NDA for govorestat (AT-007) for the treatment of Galactosemia in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.86%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
-
Rhea-AI Summary
Applied Therapeutics, Inc. plans to hold a Pre-NDA meeting with the FDA this summer to discuss a potential NDA submission for govorestat (AT-007) for the treatment of Classic Galactosemia. The company also plans to submit an EMA Marketing Authorization Application for govorestat in the fall of 2023. Applied Therapeutics believes that the clinical efficacy demonstrated so far, along with biomarker data and a favorable safety profile, may support an NDA submission. The company aims to provide further updates after the meeting with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Applied Therapeutics, Inc.

Nasdaq:APLT

APLT Rankings

APLT Stock Data

517.52M
84.90M
6.9%
69.56%
4.7%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
NEW YORK

About APLT

applied therapeutics, inc. is a hospital and health care company located in 3104 cherry palm dr, tampa, fl, united states.